Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 2, 2013, Pages 313-316

  Wallner, Lauren P ^a   Wang, Renyi ^a   Jacobsen, Steven J ^a   Haque, Reina ^a  

^a Kaiser Permanente Southern California ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER CANCER; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; GLEASON SCORE; HUMAN; KIDNEY CANCER; LOCALIZED PROSTATE CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SECOND CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84873328249     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1137     Document Type: Article

References (8)

1. Kawakami J, Cowan JE, Elkin EP, Latini DM, Du Chane J, Carroll PR, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006;106:1708-14.
2. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational studyof veteranswith prostate cancer. J Natl Cancer Inst 2010;102:39-46.
3. Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 2008;28:1511-22.
4. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivationfor prostate cancer. N Engl J Med 2005;352:154-64.
5. Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst 2010;102:1760-70.
6. Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol 2012;35:504-9.
7. Aoki K, Nakajima A, Mukasa K, Osawa E, Mori Y, Sekihara H. Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone. J Steroid Biochem Mol Biol 2003;85:469-72.
8. Izbicki JR, Hamilton SR, Wambach G, Harnisch E, Wilker DK, Dornschneider G, et al. Effects of androgen manipulations on chemically induced colonic tumours and on macroscopically normal colonic mucosa in male Sprague-Dawley rats. Br J Cancer 1990;61:235-40.